UNSPSC 51351628: Estriol succinate

This classification denotes a steroidal estrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AS13K2DY03. European Medicines Agency schedules Estriol succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07249MIG. Estriol succinate generally arises in the molecular formula C26H32O9. The term ESTRIOL SUCCINATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule estriol succinate under HS 29372300 and SITC 54153.

As of Q4 2014, ESTRIOL SUCCINATE remains US FDA's Preferred Term for this commodity. Estriol succinate bears US NLM identifiers UMLS ID C0059648 and NCI Concept Code C80784. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1C[C@H]([C@@H]2OC(=O)CCC(=O)O)OC(=O)CCC(=O)O)O.

UNSPSC 51351628 Estriol succinate is a Commodity code covering specific pharmaceutical products supplied through state and local cooperative purchasing networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Manufacturers must maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place and demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus pricing structures. All products must comply with FDA requirements, possess expiration dates of at least one year from manufacture, and be available in the marketplace by May 15, 2026. Evaluation weighting prioritizes price competitiveness (75 percent), fixed pricing for the contract term (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent).

The RFP closed to questions on February 18, 2026 with proposals due March 26, 2026. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. The contract term is two years for new responders with optional extensions at MMCAP's discretion, while incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Awarded vendors must maintain comprehensive insurance coverage including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Submissions are made through the ePro procurement system using Google Chrome with pricing and product information in designated Excel spreadsheet format converted to CSV, accompanied by supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us. Vendors must comply with performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting, missed onboarding timelines, or improper class-of-trade denials.